Answers are grounded in this paper and cite their sources.
Effectiveness of single-inhaler triple therapy on exacerbation risk and mortality in COPD is exaggerated in IMPACT and ETHOS trials from confounding by prior ICS discontinuation: effectiveness fades in analyses and studies with no prior ICS discontinuation https://bit.ly/3tOgNdW.
No takes yet. Share an insight, caveat, or question.
Samy Suissa (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: